News Author: Laurie Barclay, MDCME Author: Laurie Barclay, MDApril 4, 2008 —- The Advisory Committee on Immunization Practices (ACIP) has issued updated information on use of 7-valent pneumococcal conjugate vaccine in children aged 24 to 59 months who are not completely vaccinated, according to an article published in the April 4 issue of the Morbidity and Mortality Weekly Report.
"This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24–59 months who are either unvaccinated or who have a lapse in PCV7 administration," the report states. "In February 2000, PCV7, marketed as Prevnar and manufactured by Wyeth Vaccines (Collegeville, Pennsylvania), was approved by the Food and Drug Administration for use in infants and young children."
In October 2007, ACIP approved the following revised recommendation targeting use of PCV7 in children aged 24 to 59 months: all healthy children who have not completed any recommended schedule for PCV7 should receive 1 dose of PCV7. Routine administration of PCV7 is as a 4-dose series, given at ages 2, 4, 6, and 12 to 15 months.
All children aged 24 to 59 months who have underlying medical conditions and who have received 3 doses of PCV7 should receive 1 additional dose of PCV7. All children aged 24 to 59 months who have underlying medical conditions and who have received fewer than 3 doses should receive 2 additional doses of PCV7 given at least 8 weeks apart.
All children aged 24 to 59 months who have underlying medical conditions and who have received 3 doses of PCV7 should receive 1 additional dose of PCV7. All children aged 24 to 59 months who have underlying medical conditions and who have received fewer than 3 doses should receive 2 additional doses of PCV7 given at least 8 weeks apart.
No comments:
Post a Comment